In a report released today, Suraj Kalia from Northland Securities maintained a Hold rating on Dexcom (DXCM), with a price target of $145. The company’s shares opened today at $137, close to its 52-week high of $148.56.
According to TipRanks.com, Kalia is a 5-star analyst with an average return of 12.1% and a 59.9% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Obalon Therapeutics Inc, and Apollo Endosurgery Inc.
Dexcom has an analyst consensus of Moderate Buy, with a price target consensus of $150.
See today’s analyst top recommended stocks >>
Based on Dexcom’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $30.2 million. In comparison, last year the company had a GAAP net loss of $2 million.
Based on the recent corporate insider activity of 104 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
DexCom, Inc. is a medical device manufacturing company, which engages in the design, development, and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G4 PLATINUM System, Dexcom studio and Mobile apps.
